Advisors Preferred LLC Sells 18,353 Shares of Cencora, Inc. $COR

Advisors Preferred LLC cut its position in Cencora, Inc. (NYSE:COR) by 96.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 767 shares of the company’s stock after selling 18,353 shares during the period. Advisors Preferred LLC’s holdings in Cencora were worth $239,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Norges Bank bought a new stake in shares of Cencora in the second quarter valued at about $695,215,000. Mizuho Markets Americas LLC boosted its holdings in shares of Cencora by 116.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock worth $66,506,000 after buying an additional 1,511,906 shares during the period. Artisan Partners Limited Partnership acquired a new stake in Cencora during the 2nd quarter worth approximately $411,888,000. Vanguard Group Inc. grew its stake in shares of Cencora by 5.3% in the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after acquiring an additional 1,125,661 shares in the last quarter. Finally, Viking Global Investors LP grew its position in Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after buying an additional 1,013,913 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the subject of several recent analyst reports. Robert W. Baird set a $415.00 target price on Cencora in a research note on Tuesday, January 13th. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. UBS Group boosted their price target on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Barclays increased their target price on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $399.00.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the transaction, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This trade represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 15,220 shares of company stock worth $5,282,867 in the last quarter. Company insiders own 0.38% of the company’s stock.

Cencora Price Performance

Shares of Cencora stock opened at $360.70 on Monday. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The company’s fifty day simple moving average is $349.41 and its two-hundred day simple moving average is $331.39. The firm has a market cap of $70.17 billion, a PE ratio of 43.35, a price-to-earnings-growth ratio of 1.68 and a beta of 0.68. Cencora, Inc. has a 12-month low of $240.72 and a 12-month high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. The business had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the prior year, the business earned $3.73 EPS. As a group, equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s payout ratio is presently 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.